MINNEAPOLIS, MN, US, Aug. 25, 2021 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets is pleased to announce that Ann Zieser, DVM has accepted a position with the Company as its new Senior Technical Veterinarian.
"We are incredibly excited to have Ann join the PetVivo team and provide her extensive veterinary expertise to further the vision of PetVivo and aid other vets in the treatment of companion animals.” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “Dr. Zieser brings a wealth of experience to our team as an expert in veterinary medicine and the therapeutic treatment of cats, dogs and horses."
Dr. Zieser began her career as a companion animal practitioner at Middleton Veterinary Hospital (“MVH”) located outside Madison, Wisconsin. Thirty-one years later she continues to work at MVH treating companion dogs and cats performing diagnostics, internal medicine, radiology, surgery, dentistry to name just a few disciplines. Dr. Zieser has further contributed to the veterinary community as the secretary of the local Dane County Veterinary Medical Association. Following several different volunteer positions within the Wisconsin Veterinary Medical Association, Dr. Zieser elevated her participation by accepting the role as President-Elect of the Wisconsin Veterinary Medical Association. Dr. Zieser has further climbed from local and state organized veterinary medicine into the national arena as the American Veterinary Medical Association alternate delegate and then delegate for the state of Wisconsin. Dr. Zieser has a degree in biochemistry from the University of Wisconsin – Madison and a Doctorate in Veterinary Medicine from UW-Wisconsin School of Veterinary Medicine.
“I am thrilled to join the PetVivo team and participate in the effort to introduce the therapeutic benefits of SPRYNG™ to companion animals suffering from osteoarthritis and other lameness afflictions,” said Dr. Zieser. “I am confident that SPRYNG™ will enhance the lives of companion animals, as well as their owners.”
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG, a veterinarian-administered, intraarticular injection for the treatment of osteoarthritis in dogs and horses, is scheduled for expanded commercial sale later this year.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking commercial Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements, including the potential listing of the Company’s common stock on Nasdaq, are based on information currently available the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2020 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Attachment
